Key Takeaways for CVS Health Stock as of July 2026
- Valuation Gap: TIKR’s mid case model values CVS Health stock at $132 by December 2030, a 22% total return from today’s $108 price and 5% annualized over 4.4 years.
- Analyst Split: Eighteen analysts rate CVS Health stock buy, six call it outperform, four say hold, and none recommend selling.
- Guidance Raise: CVS lifted full year adjusted EPS guidance to $7.30 to $7.50 after Q1 EPS grew 14% YoY to $2.57.
- Drawdown Setup: Shares sit 3% below their high, deep inside a 16% drawdown.
CVS Health Raises 2026 EPS Guidance as Aetna Margins Rebound Fast
CVS Health (CVS) delivered adjusted earnings per share of $2.57 in the first quarter of 2026, up 14% year over year, and used that momentum to raise full year adjusted EPS guidance to a range of $7.30 to $7.50 from $7.00 to $7.20. The $0.30 increase traces almost entirely to one segment: Health Care Benefits, the Aetna insurance business that spent most of 2025 losing money on Medicare Advantage.
Aetna’s medical benefit ratio, the share of premiums paid out in claims, fell to 84.6% in the quarter. CFO Brian Newman said the improvement stemmed from favorable prior year development in the government business, plus what he called pockets of core outperformance from strong medical cost management. That favorable development pushed full year Health Care Benefits adjusted operating income guidance up $420 million, to a range of $4 billion to $4.34 billion.
That caution extends to capital return. CVS held its quarterly dividend at $0.67 per share for an eighth straight quarter, and CFO Brian Newman confirmed buybacks aren’t in the 2026 guide even after leverage improved to 3.84 times, ahead of the company’s own target.
CVS chose not to extend that optimism to its full year medical cost trend view. Management held full year MBR guidance at 90.5% plus or minus 50 basis points, calling it a respectful and prudent stance until more of the year plays out. CFO Brian Newman addressed that trajectory directly when asked about Aetna’s path back to target margins: “We’ve got tremendous earnings power at Aetna and we see a pathway back to target margins, as you mentioned, by ’28.”
That gap between a raised near term guide and an unchanged full year trend assumption is the real story. CVS is banking real dollars from a one-time reserve benefit while still treating 2026’s underlying cost trend as unresolved, which means the market has more visibility into Aetna’s earnings power than it had six months ago, but not yet proof the core business has turned.
Every quarter that Aetna’s MBR beats expectations without a downward revision to guidance tightens the case that CVS Health stock is still pricing in more Medicare Advantage risk than the fundamentals now support.
CVS Health Stock Trades Near Its High After a 16% Drawdown
CVS Health stock hit its worst drawdown of the past year on March 27, 2026, falling 16% from its prior peak, before the Q1 print and guidance raise helped it claw back nearly all of that loss.
Shares now sit just 3% below their high, a sharp reversal from a decline that predates the reserve benefit CVS is now citing as reason for optimism.
Street analysts remain more bullish than bearish on CVS Health stock, with 18 buy ratings, six outperforms, and four holds, and not a single sell rating among the 26 analysts covering the name. The mean price target sits at $112, which puts the stock just 4% below where Wall Street expects it to trade, a gap that has narrowed sharply since the target sat at 134% of the stock price back in March 2026.
That narrowing had specific triggers. Bernstein raised its target to $106 from $94 in May, and Mizuho lifted its own to $110 from $102, both pointing to the same Medicare Advantage margin recovery driving the MBR beat.
TIKR Values CVS Health Stock at $132, Pricing In Aetna’s Margin Recovery
TIKR’s mid case model values CVS Health stock at $132 by December 2030, implying a 22% total return from the current price of $108, or 5% annualized over the next 4.4 years.
That return sits well below the mid-teens EPS growth CVS itself has guided to through 2028, suggesting the model is pricing a slower path to target margins than management’s own commentary describes. Still, a 5% annualized return from a stock still working through a Medicare Advantage repair job is a different proposition than the same return from a business with no turnaround left to prove.
The target is reachable because the $420 million lift to Health Care Benefits guidance already shows Aetna’s earnings power moving in the right direction, even before the full year MBR assumption gets revised down. If CVS converts even a fraction of that prior year reserve benefit into a genuine core trend improvement over the next several quarters, the gap between the Street’s cautious 4% implied upside and TIKR’s 22% total return case starts to close.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
